Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus GILDESS FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus GILDESS FE 1 20.
ENOVID-E vs GILDESS FE 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Ethinyl estradiol: terminal half-life approximately 13 hours (range 10-15 h). Desogestrel: metabolized to etonogestrel; etonogestrel terminal half-life about 28 hours (range 20-40 h). Clinical context: steady-state reached within 7-10 days.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Approximately 60-65% renal (as metabolites), 30-35% fecal (as metabolites and unchanged drug). Ethinyl estradiol and desogestrel metabolites are excreted primarily via urine and feces. Etonogestrel (active metabolite) is excreted mainly via feces (40%) and urine (32%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive